Eckard Weber, MD
Partner, Domain Associates

Dr. Weber is a partner at Domain Associates where he creates companies around promising new pharmaceutical products. He has been founding CEO of multiple biopharmaceutical companies in the Domain portfolio including Cytovia, Acea, Novacea, NovaCardia, Novalar, Orexigen, Domain Antibacterial Acquisition Corporation, Ascenta, Ocera, Syndax, Tragara, Tobira, Sonexa and Calixa. He currently serves as interim CEO of Sonexa and Calixa, two seed-stage biopharmaceutical companies. He is Chairman of the Board at NovaCardia, Orexigen, Ocera, Ascenta, Tobira and Syndax. He was Chairman of Peninsula until it’s sale to Johnson & Johnson in 2005, Chairman of Cerexa until it’s sale to Forest Laboratories in January 2007, and a Board member of Conforma and Cabrellis until their sales to Biogen-IDEC and Pharmion, respectively. In addition, he is a board member of DiObex and BioVascular, Inc. Until 1995, Mr. Weber was a tenured Professor of Pharmacology at the University of California at Irvine. He has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. He is the inventor or co-inventor of over 40 patents and patent applications, and he has published over 130 papers in scientific periodicals.